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Background
A more systematic study of correlation of vitamin B12 lev-
els and mental health. During the patient's stay in our
clinic ward she mentioned hemodia, unstable walking,
and a not elucidatory determinative weakness at both
hands. After full neurological examination, we moved to
the examination of B12 levels. As these levels were 150 pg/
mL we started substitute treatment, provided that the
patient had been taking antiepileptic medicine for years
and had low toxicity of B12. At following neurological
examinations the clinical icon of the patient had obvi-
ously improved. Carbamazepine and sodium valproate
are widely used as maintenance treatment of bipolar dis-
order.Although the alteration of accumulation of B12 in
serum is not totally acceptable by scientists [1], [2], [3],
there are indications for the relation between antiepileptic
medicine and reduced levels of B12 at least at cerebrospi-
nal fluid folate [4]. Additionally, the combination of any
inefficiency with the chronic alcoholism that is often
present in this category of mental patients and the rise of
life expectancy creates the need of a bigger demanded
quantity of B12 in their diet.
Materials and methods
A female patient, with bipolar disorder II. Psychiatric and
physical examination, laboratory tests, scientific review.
Results
It has been over 20 years when an incident of a maniac
patient without megaloblast anemia has been reported for
the first time [5]. The role of B12 at nervous system func-
tion is widely known, either it concerns the spinal marrow
disorders (dorsal and side phacycilus) or the anoia as
pathogenic factor.It is obvious that the B12 can improve
the neurologic symptoms of patients who receive chronic
antiepileptic drug treatment, even though they do not
have anemia [6].
Conclusions
It is worth taking into account if the test of B12 levels can
or must be introduced in routine laboratory tests.
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